99 Wall Street, Suite 232, New York, NY 10005

Need Help? Call : (800) 991-3756

Class Action Cases

A class action has been filed on behalf of TEVA Investors. Click "Join this Class Action" above.


Teva Pharmaceuticals Industries Limited

Join Class Action »

Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Teva Pharmaceuticals Industries Limited (NYSE: TEVA) from October 29, 2015 through August 18, 2020 (the “Class Period”). The lawsuit seeks to recover damages for Teva Pharmaceuticals Industries Limited investors under the federal securities laws.

If you bought Teva Pharmaceuticals Industries Limited securities between  October 29, 2015 through August 18, 2020, and would like to join the action, please click “Join This Class Action,” above.

Press Release

SHAREHOLDER ALERT: Zhang Investor Law Announces a Securities Class Action Lawsuit Against Teva Pharmaceuticals Industries Limited – TEVA

New York, N.Y., November 12, 2020. Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Teva Pharmaceuticals Industries Limited (NYSE: TEVA)  between October 29, 2015 and August 18, 2020, inclusive (the “Class Period”).

To join the TEVA  class action, go to http://zhanginvestorlaw.com/cases/teva-pharmaceuticals-industries-limited/ call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time.

According to the lawsuit,  throughout the Class Period (1) Teva had made substantial illegal kickback payments to charitable foundations to cover Medicare co-payment obligations of patients taking Copaxone; (2) accordingly, Teva’s revenues derived from Copaxone were in part the product of unlawful conduct and thus unsustainable; (3) the foregoing misconduct subjected Teva to a foreseeable risk of heightened regulatory scrutiny and enforcement, as well as reputational harm when the truth became known; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 23, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/teva-pharmaceuticals-industries-limited/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at info@zhanginvestorlaw.com.

Zhang Investor Law represents investors worldwide.